These payloads stimulate immune-cell sensors that recognize danger. The goal is to direct immune activation toward a tumor using an antibody.
TLR7/8 agonist antibody conjugates have induced myeloid activation and adaptive immune responses in preclinical studies. The Ackerman study required tumor-antigen recognition, Fc-receptor-dependent phagocytosis and TLR activation, rather than payload toxicity alone. BDC-1001 and SBT6050 are human-study examples. The BDC-1001 registry studies are terminated; one SBT6050 study is of unknown status and another is terminated. Unknown status should not be presented as recruiting.
Showing the technology this term belongs to: Antibody-drug conjugate (ADC).
Shares Immune-stimulating antibody conjugate (ISAC), Next-generation antibody-conjugate payloads, Payload (ADC), Antibody-drug conjugate (ADC).
Shares Next-generation antibody-conjugate payloads, Payload (ADC), Antibody-drug conjugate (ADC).
Shares Next-generation antibody-conjugate payloads, Payload (ADC), Antibody-drug conjugate (ADC).
Shares Next-generation antibody-conjugate payloads, Payload (ADC), Antibody-drug conjugate (ADC).
Shares Next-generation antibody-conjugate payloads, Payload (ADC), Antibody-drug conjugate (ADC).
Shares Next-generation antibody-conjugate payloads, Payload (ADC), Antibody-drug conjugate (ADC).
Shares Next-generation antibody-conjugate payloads, Payload (ADC), Antibody-drug conjugate (ADC).
Shares Next-generation antibody-conjugate payloads, Payload (ADC), Antibody-drug conjugate (ADC).
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/